A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers

Por Smith, Patrick F., Krishnarajah, Janakan, Nunn, Philip A., Hill, Ron J., Karr, Dane, Tam, D., Masjedizadeh, Mohammad, Funk, Jens O., Gourlay, Steve G.
Publicado no Br J Clin Pharmacol (2017)